Like in NSCLC targeted therapy and immunotherapy from liquid biopsy, specific gene alterations and mutations of EGFR, rearrangements of the anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) provide guidance for treatment decisions [30]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.